ABSTRACT -Gatifloxacin has been associated with increased risks of hypoglycemic and hyperglycemic side effects. In order to understand the molecular mechanism of gatifloxacin induced deregulation of glucose metabolism, a combination of comparative and chemical proteomic approaches were employed using yeast as a model system. Differential protein expression studies using two dimensional electrophoresis and mass spectrometry reveal that gatifloxacin deregulates the expression of key enzymes involved in glucose metabolism. Furthermore, affinity chromatography and LC-MS E analysis led to identification of enolase, as one of the key gatifloxacin binding proteins. Fluorescence spectrometric studies confirmed that the gatifloxacin indeed binds to enolase. Role of enolase in regulation of gatifloxacin induced dysglycemic effect is discussed.
INTRODUCTION
Gatifloxacin is one of the fourth generation fluoroquinolones used as an antibiotic, which acts by inhibiting bacterial topoisomerase II and DNA gyrase 4 (Takei et al., 2002) . Although gatifloxacin was withdrawn from the US market, the drug is still being used extensively in other parts of the world for treatment of multidrug-resistant infectious diseases. The drug was withdrawn because of the fact that it exhibits acute hypoglycemic and chronic hyperglycemic side effects (Frothingham, 2005; Lewis and Mohr, 2008; Mehlhorn and Brown, 2007, Onyenwenyi et al., 2008; Zvonar, 2006) . The acute hypoglycemic effect could be due to increased insulin secretion triggered by inhibition of ATP dependent potassium channel in the beta cells of pancreas (Saraya et al., 2004; Yamada et al., 2006) . Additionally, a recent study suggests that the gatifloxacin affects gluconeogenesis by inhibiting pyruvate transport to mitochondria (Drozak et al., 2008) . In animal studies, gatifloxacin has been shown to increase epinephrine release when given in higher doses, thus increasing the metabolic rate leading to hypoglycemic condition (Ishiwata et al., 2006) . In contrast, chronic hyperglycemic effect could be due to the down regulation of glucose transporter 1 (GLUT1) expression in presence of gatifloxacin (Ge et al., 2007 (Ge et al., , 2009 . Interestingly, in the same study, it was also demonstrated that the gatifloxacin increases the GLUT1 promoter activity and decreases the mRNA levels of the gene suggesting that the drug affects the stability of the GLUT1 mRNA by a mechanism yet to be understood. Gatifloxacin effect on glucose metabolism could be also due to altered protein expression. It is important to understand the influence of gatifloxacin on the regulation of enzymes involved in glucose metabolism.
Yeast (Saccharomyces cerevisiae) has been considered as an excellent model system to study glucose metabolism as the pathways have been conserved (Sanz, 2007) . Comparative genomic studies have revealed the yeast genome is highly conserved in higher eukaryotes as evidenced by the non redundant protein sets (Rubin et al., 2000) . The knowledge about the transcription regulatory networks, protein -protein interaction maps, metabolomic pathways of yeast gives a coherent picture of core glucose metab-olism. Several studies have shown that yeast is a useful model system for studying drug toxicity, as well in drug discovery process likes identification of anticancer, antiaging, metabolic disorders, oxidative stress, etc (Netzer and Breitenbach, 2010; Fabrizio and Longo, 2003; Hughes, 2002; Giaever et al., 1999) . Although there are imitations to use yeast to identify potential side effects of drugs of human use, yet it can reveals some of the mechanisms of drug action as well as toxicity (Steinmetz et al., 2002; Perocchi et al., 2008; Koch et al., 1993) . In the present study we report the influence of gatifloxacin on the protein expression with a special emphasis to proteins involved in glucose metabolism using yeast as a model system by combination of comparative (Bandow et al., 2003; Wishart, 2007; Hoon et al., 2008) and chemical proteomic approaches (Rix and Superti-Furga, 2009 ). Further, we studied the interaction of gatifloxacin with enolase by fluorescence spectrometry.
MATERIALS AND METHODS

Materials
YPD Medium for yeast culture was obtained from Hi-media India, BioLyte 3-10 carrier ampholytes and IPG strips were obtained from Bio-Rad (Banglore, Karnataka, India), proteomic grade trypsin was from Sigma -Aldrich (Banglore, Karnataka, India), and acetonitrile (MS grade) was purchased from Fisher Scientific (Mumbai, Maharashtra, India). Water (18.2 MΩ) for all experiments was distilled and purified by Milli-Q synthesis (Milli-Q), and all other chemicals were purchased from SigmaAldrich. Gatifloxacin was obtained from Emcure Pharmaceutical Ltd. (Pune, Maharashtra, India).
Yeast culture and minimum inhibitory concentration (MIC) of gatifloxacin
The Saccharomyces cerevisiae (NCYC 957) strain was used to study the influence of gatifloxacin on proteins involved in glucose metabolism. Cells were batch-cultured in YPD 2% growth medium at 28°C with a constant rotation at 200 rpm. Minimum Inhibitory concentration (MIC 50 ) of gatifloxacin was determined by growing cells on different concentration of gatifloxacin ranging from 60 mg/l to 250 mg/l for 18 hr at 28°C (Andrews, 2002) . The growth of yeast was spectrometrically monitored at 600 nm.
Glucose utilization by yeast
Glucose utilization by yeast was analyzed in both control and gatifloxacin treated yeast culture by monitoring the residual glucose with a glucose-oxidase-peroxidase reaction kit (Merck). At different points of time, supernatant of YPD medium was separated from the yeast cells by centrifugation at 4,000 g for 10 min. 10 μl of supernatant was used to analyze glucose.
Protein extraction
Protein was extracted in buffer containing 7 M Urea, 2 M Thiourea, 4% CHAPS, 1% DTT and 2% general protease inhibitor cocktail (Sigma Chemicals, Banglore, Karnataka, India). Yeast cells were sonicated for 30 sec and the sample was cooled in ice for 2 min and this cycle was repeated thrice. The cell lysate was centrifuged at 10,000 g for 30 min. The supernatant was collected and precipitated with 80% cold acetone containing 10% TCA and incubated at -20°C for overnight, Precipitate was centrifuged at 10,000 g for 30 min at 4°C and the pellet was resolubilized in rehydration buffer (7 M Urea, 2 M Thiourea, 4% CHAPS, 1% DTT and 2% 3-10 Biolyte Ampholytes from Bio-Rad). The protein concentration was determined by Bradford method.
Two dimensional electrophoresis
Isoelectrofocusing (IEF) was carried out on linear narrow range immobilized pH gradients strips of 17 cm (pH 5-8, Bio-Rad) using Protean Isoelectric focusing system (Bio-Rad). The voltage was set to 250 V for 1 hr, and then ramped to 10,000 V for 3 hr, which was continued at 10,000 V until 72,000 Vh reached. IPG strips were equilibrated with dithiothreitol and iodoacetamide and a second-dimensional electrophoresis was performed by using 12% SDS-PAGE. Gels were stained with coomassie brilliant blue to visualize the protein spots. Images were acquired using GS 800 densitometer (Bio-Rad) and data analysis was carried out by PDQuest advanced software (Bio-Rad). Protein spots in each gel image were initially detected using the PDQuest spot detection wizard, followed by editing to remove incorrectly detected artifacts. A master image of combined spots from both gels was used for image analysis. Analysis was carried out for three biological replicates. Normalization factor was calculated between different replicates using the total optical density of the gel. The density of each protein was expressed as mean ± S.D. for three experiments. The statistical significance was established by Students t-test. Differences were considered significant if p ≤ 0.05.
Affinity chromatography
An affinity chromatography of gatifloxacin was developed by immobilizing carboxylic group of the drug onto Affigel-102 resin using EDAC coupling as described in Fig. 1 for chemical proteomic analysis. The resin (bed volume 1 ml) was packed in a 2.5 ml chromatography column and equilibrated with MilliQ water (pH was adjusted to 4.7-5 with HCl). Gatifl oxacin (10 mg) dissolved in 1 ml of water (pH 4.7-5) was applied onto Affi gel-102, to which 10 mg EDAC coupling reagent was added. The reaction mixture was kept at room temperature for 4 hr. After the reaction, the column was washed with milliQ water (pH 4.7) to remove unbound gatifloxacin. Coupling of gatifl oxacin to the resin was monitored spectrometrically by measuring the unbound drug at 287.5 nm, which is the A max for gatifloxacin. Drug bound Affigel -102 was washed with equilibration buffer containing 250 mM ammonium acetate, 50 mM magnesium chloride, 0.01% triton X-100 buffer (pH 8.8). Protein lysate (1.5 mg) extracted from yeast in equilibration buffer (250 mM ammonium acetate, 50 mM Magnesium chloride, 0.01% Triton X-100 buffer pH 8.8) containing 50 μl/ml of general protease inhibitor (Sigma), was incubated with gatifloxacin immobilized on to affigel beads. The column was washed thoroughly to remove unbound protein. Washing was continued till the A280 reading was stabilized. Bound proteins were eluted with gatifl oxacin (10 mg/ml) dissolved in ammonium acetate buffer. The eluate containing proteins was concentrated by lyophilisation and further digested with trypsin.
Mass spectrometry analysis and protein identifi cation
The proteins separated on two dimensional electrophoresis gel and digested peptides were analyzed using the Applied Biosystems 4800 MALDI-ToF/ToF Analyzer (Applied Biosystems, Inc., Framingham, MA, USA) at IISER, Pune. The instrument was calibrated to less than 10 ppm accuracy by using a calibration mixture of known standard peptides within a mass range of 800 to 4,000 m/z. Samples were analyzed in positive ion refl ector mode. Data dependent tandem mass spectrometry of 20 most intense peptides from MS scan (PMF) of individual protein was performed with 0.6 μl reconstituted extract mixed with a 0.6 μl fresh α-cyano-4-hydroxycinnamic acid (CHCA) (Applied Biosystems) matrix on a 384-well MALDI target plate. PMF and MS/MS data were analyzed with global proteomic solutions software (GPS Explorer, version 3.6; Applied Biosystems) and further interrogated for protein identification with the SWISSPROT database by using Mascot search engine. The search parameters for protein identification were set as follows; fixed and variable modifications were carbamidomethyl cysteine and methionine oxidation respectively. Mass tolerances of 50 ppm, requirement of at least five peptides matched, and a maximum of two missed cleavages, were used for protein identification. A protein was considered to be identifi ed correctly with a Mascot score of above 60. Proteins isolated by affi nity chromatography were identifi ed by nano-LC-MS E approach using nano-Acquity-Synapt-HDMS system (Waters Corporation, Milford, MA, USA). Proteins eluted by affi nity chromatography were digested in solution. Reduction and alkylation of proteins was carried out by using DTT and iodoacetamide respectively and digested with trypsin. 4 μl of peptides was loaded on the nano-LC. Peptides were trapped on a 5 μm Symmetry C18 column (180 μm × 20 mm) and washed for 3 min at 5 μl/min with mobile phase A (0.1% formic acid). Peptides were then separated and eluted for MS analysis using a 60 min reverse phase gradient at 400 nl/min (5-50% ACN over 35 min) on a BEH 130 C18 1.7 μM x 100 μM x 100 mm nano Acquity UPLC column. The column temperature was set at 35°C. The reference ([Glu1]-fibrinopeptide B, 500 fmol/ml) was constantly infused by the nano Acquity auxiliary pump at a constant fl ow rate of 500 nl/min at an interval of 20 seconds. The eluted peptides spectra were acquired by Synapt-HDMS (Q-TOF) with following parameters. Sample was analyzed in positive V mode in a mass range of 50-2,000 m/z with a scan time of 1.5 sec. The on-line eluted peptides were analyzed at both low collision energy (4 eV) and high col- lision energy (15-35 eV). LC-MS E data were processed with ProteinLynx GlobalServer v2.3 (Waters Corporation, Milford, MA, USA) and searched with Saccharomyces cerevisiae data base (UniProtKB) for protein identifi cation (Patel et al., 2009; Silva et al., 2006) Fluorescence quenching by gatifl oxacin To study the interaction of gatifl oxacin with its interacting proteins, fluorescence quenching was studied in presence of different concentration of gatifloxacin. A Varian Cary Eclipse fluorescence spectrophotometer equipped with 1.0 cm path length with a Varian multicell peltier temperature controller was used to measure the fl uorescence and the fl uorescence intensity. Fluorescence quenching spectra were obtained by scanning the emission spectra from 300 nm to 500 nm at the excitation wave length of 295 nm, with a slit width of 10 nm. The stock solutions of gatifl oxacin and its interacting protein were prepared in 50 mM Tris-HCl (pH 7.4) (Guo et al., 2004) .
RESULTS AND DISCUSSION
In this study we have specifi cally attempted to understand the influence of gatifloxacin on the regulation of proteins involved in glucose metabolism using yeast Saccharomyces cerevisiae, which has been considered as a model organism to study glucose metabolism (Hughes, 2002; Simon and Bedalov, 2004) . In order to study the infl uence of gatifl oxacin on proteins involved in glucose metabolism MIC 50 of gatifl oxacin was determined by its ability to inhibit yeast growth rate by 50% after 18 hr (Andrews, 2002) . The MIC 50 of gatifl oxacin was found to be 154 mg/l ( Supplementary Fig. 1) ; the same concentration was used to study the effect of gatifl oxacin on glucose utilization and differential protein expression. Glucose utilization by yeast was monitored by residual glucose in the medium. In presence of gatifloxacin per cent residual glucose was higher in the medium compared to control at similar number of yeast cells. For example control yeast cells showing absorbance of 1.0 had lower residual glucose than that of yeast cells grown in presence of gatifl oxacin, suggesting that the glucose utilization was reduced in presence of drug (Fig. 2) . Further, gatifl oxacin induced differentially protein expression was studied using two dimensional electrophoresis and mass spectrometry. Differentially expressed proteins were listed in Table 1 , and those specifi c to glucose metabolism were depicted in Figs 3A and B. Many of the differentially expressed proteins were involved in glucose metabolism; few proteins were involved in stress response, and gene regulation. Nine proteins identifi ed were involved in glucose metabolism especially six of them belong to glycolytic pathway including alcohol dehydrogenase, triose phosphate isomerise, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), enolase 1, enolase 2, fructose bisphosphate aldolase, pyruvate decarboxylase isozyme 1 (PDC Isozyme 1). Expression of phosphofructokinase, GAPDH, triose phosphate isomerase, enolase 1 and enolase 2 were down regulated in presence of gatifl oxacin. A Similar results were observed in a comparative proteomics study of Pasteurella multocida-a gram negative bacteria, where enorofl oxacin, a fl uoroquinolone signifi cantly decreased the expression of phosphoenolpyruvate carboxykinase, phosphoglycerate kinase, fructose bisphosphate aldolase, and glyceraldehyde-3-phosphate dehydrogenase (Nanduri et al., 2006) . On the other hand in this study, pyruvate decarboxylase isozyme 1, fructose biphosphate aldolase and alcohol dehydrogenase were upregulated by gatifl oxacin. By and large, majority of the proteins involved in glucose metabolism were affected by gatifl oxacin. Gatifl oxacin induced chronic dysglycemic effect in human beings could be due to differential regulation of the enzymes involved in glucose metabolism. Besides proteins involved in glucose metabolism, stress induced proteins such as heat shock protein SSA 1 and thiol specific antioxidant protein were down regulated and were not detected by coomassie staining. The other protein upregulated in presence of gatifl oxacin was Elongation factor 2 (EF-2), involved in protein synthesis. In short, the major outcome of the gatifl oxacin induced dif- ferential expression analysis of protein suggests that the enzymes involved in glucose metabolism are the major targets of gatifloxacin.
Chemical proteomics is the method of choice to identify the drug interacting proteins as well as to understand the mechanism of differential regulation of enzymes (Bantscheff et al., 2007; Jeffery and Bogyo, 2003) . In this study we used chemical proteomics approach to understand the molecular mechanism of differential regulation of enzymes involved in glucose metabolism, as well as to identify gatifloxacin interacting proteins. The carboxyl group of gatifloxacin was immobilized onto Affigel-102 (Bio-rad) and its binding proteins were isolated by affinity chromatography Fig 1. By chemical proteomics approach, it was possible to identify Enolase 1 (ENO1), glyceraldehyde 3 phosphate dehydrogenase 1 GAPDH), pyruvate decarboxylase isozyme 1 (PDC1) as gatifloxacin interacting proteins (Table 2) . Enolase was one of the most abundant proteins in the eluate as reflected by more number of peptides and sequence coverage in the LC-MS E analysis. Therefore, enolase was selected for further in vitro binding kinetic studies with gatifloxacin by fluorescence quenching approach. An obvious decrease in tryptophan fluorescence of enolase was observed with increasing concentration of gatifloxacin as depicted in Fig. 4a . However, this trend was not observed with lysozyme, which was used as a negative control for gatifloxacin binding (Supplementary Fig. 2) . In order to understand the fluorescence quenching mechanism Stern-Volmer equation was plotted as shown in the Fig 4B using the following formula (1) (Guo et al., 2004; Liu et al., 2007) .
Where F0 and F are the fluorescence intensities in the absence and presence of a quencher (gatifloxacin), Ksv and [Q] are the dynamic quenching constant, and concentration of the quencher, respectively. Stern-Volmer constant for enolase upon gatifloxacin binding was 0.82 10 -4 l . mol -1 . Dynamic quenching of fluorescence has been The protein fold change above 1.5 and below 0 .75 were listed with a p value < 0.05 (student's t-test). (n = 3) UniProtKB accession numbers were given along with its molecular weight, pI, coverage and probability. Gatifl oxacin binding proteins were isolated by affi nity chromatography and were identifi ed by nano-LC-MS. (n = 3). UniProtKB accession number was given. 
(a) (c) (b)
fl oxacin interacts with enolase by affi nity chromatography and fl uorescence experiments. However, it is important to establish the biological significance of this interaction.
The role of these gatifloxacin binding proteins and probable mechanism of gatifloxacin action has been depicted in Fig. 5 . All the three proteins viz. enolase, GAPDH, PDC isozyme, have regulatory functions on glucose metabolism at different levels including transcription, translation and post translational mechanisms. GAPDH is multifunctional protein, involved in, transcriptional regulation, cell death, cell signalling pathways and glucose transportation (King et al., 2004) . GAPDH may have a role in gatifl oxacin induced dysglycemia due to its involvement in insulin signalling pathway, as well as by enhanced glucose transport by infl uencing GLUT4 activity (Min et al., 2007; Sheng and Wang, 2009 ). Pyruvate decarboxylase isozyme 1 (PDC1) is the other enzyme identified to be gatifloxacin binding protein. It is the key enzyme involved in alcoholic fermentation through the degradation of pyruvate into acetaldehyde and carbon dioxide. Recently, it was shown that the gatifl oxacin affects gluconeogenesis by decreasing pyruvate transport to mitochondria (Drozak et al., 2008) . However, enolase may have a greater role in gatifl oxacin induced dysglycemic effect as shown by our study with affi nity chromatography and fl uorescence quenching, as well as several previous studies indicate a role for enolase in regulation of glucose metabolism. Enolase is involved in several functions ranging from glucose metabolism, transcription to apoptosis (Morita et al., 2004; Subramanian and Miller, 2000) . Enolase activity with respect to regulation of glucose metabolism is through mRNA degradation of GLUT1, as well as down regulation of transcription factor c-myc. The mRNA degradation of GLUT1 is carried out by a multienzyme complex called RNA degradosome (Morita et al., 2004) . Enolase acts as switch to GLUT1 mRNA degradation by binding to RNA degradosome complex. Thus it plays a crucial role in the regulation of GLUT1 mRNA stability. This was evidenced by a recent study, where it was also demonstrated that the gatifl oxacin decreases the mRNA levels of the GLUT1 gene (Ge et al., 2009) . However, the molecular mechanism of gatifl oxacin induced GLUT1 mRNA degradation was not been established so far. Gatifl oxacin may affect the stability of the GLUT1 mRNA through interaction with enolase, a component of RNA degradosome complex. Additionally, enolase has been shown to down regulate c-myc and thereby decrease the expression of glucose transporter GLUT1, phosphoglucose isomerase, phosphofructokinase (PFK), glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, and enolase. In this study also, it was observed that the expression of ENO, GAPDH, and PFK was down regulated. Enolase controls GLUT1 expression at both transcriptional and translational levels. Together comparative and chemical proteomic approaches suggest that gatifloxacin regulates glucose metabolism at various levels, in addition to its previous role in insulin secretion (Saraya et al., 2004; Yamada et al., 2006) .
In conclusions, two dimensional electrophoretic studies combined with mass spectrometric analysis suggest that the enzymes involved in glucose metabolism were deregulated by gatifloxacin. Additionally, affinity chromatography revealed that gatifloxacin interacts with enolase, GAPDH, and PDC. Fluorescence quenching experiment further confirms that gatifloxacin interacts with enolase. Both studies, comparative and chemical proteomic approaches suggest that gatifloxacin affects the enzymes involved in glucose metabolism perhaps by regulating at different levels including mRNA degradation, gene expression, glucose transport and metabolism.
